RxDoctor Payments Data

Ian McWherter

Optometrist · Louisville, KYNPI 1770838732

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by AbbVie at 36.0% of the total. Among optometrist clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,944in general payments, 2019–2025

Across 283 payments — averaging $63.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Glaukos Corporation$3K
  • Bausch & Lomb Americas Inc.$2K
  • Alcon$1K
  • Novartis$848
  • Sun Pharmaceutical Industries Inc.$647
  • plus $4K from 25 others

What the payments were for

  • Consulting fees$3,80021%
  • Speaking & faculty fees$4,45025%
  • Travel & lodging$1281%
  • Food & beverage$9,46653%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,944 in reported general payments places this provider in the 95th percentile of 712 optometrist providers in Kentucky.

See all optometrist providers in Kentucky

Medicare billing

Part B allowed, 2024
$314,217
Medicare patients
880
Services billed
4,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine827$648,331
Cyclosporine366$169,828
XiidraLifitegrast108$121,734
RocklatanNetarsudil Mesylat/Latanoprost263$101,760
XdemvyLotilaner41$78,135
MieboPerfluorohexyloctane/Pf82$64,278
LumiganBimatoprost99$37,150
CombiganBrimonidine Tartrate/Timolol148$35,774
RhopressaNetarsudil Mesylate57$20,303
LotemaxLoteprednol Etabonate43$20,018
Fluorometholone204$19,868
Alphagan PBrimonidine Tartrate54$19,398
TyrvayaVarenicline Tartrate28$19,389
Dorzolamide-TimololDorzolamide/Timolol/Pf128$16,086
SimbrinzaBrinzolamide/Brimonidine Tart64$15,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$6,466$740,6531,128 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta, Zirgan$1,855$207,999257 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$406$122,063320 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$550$78,13541 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax, Prolensa, Lotemax Sm, Loteprednol Etabonate$244$48,296145 claims
Oyster Point Pharma, Inc.Tyrvaya$166$19,38928 claims
AlconSimbrinza$1,197$15,65664 claims
Eyevance Pharmaceuticals LLCFlarex$54$8,01262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 712 optometrist providers in Kentucky.

Other optometrist in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →